CN104861071A - 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 - Google Patents
针对pcsk9的全人源单克隆抗体的可变区基因及其应用 Download PDFInfo
- Publication number
- CN104861071A CN104861071A CN201510205553.5A CN201510205553A CN104861071A CN 104861071 A CN104861071 A CN 104861071A CN 201510205553 A CN201510205553 A CN 201510205553A CN 104861071 A CN104861071 A CN 104861071A
- Authority
- CN
- China
- Prior art keywords
- pcsk9
- variable region
- antibody
- sequence
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510205553.5A CN104861071B (zh) | 2015-04-27 | 2015-04-27 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510205553.5A CN104861071B (zh) | 2015-04-27 | 2015-04-27 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104861071A true CN104861071A (zh) | 2015-08-26 |
CN104861071B CN104861071B (zh) | 2019-04-12 |
Family
ID=53907296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510205553.5A Active CN104861071B (zh) | 2015-04-27 | 2015-04-27 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104861071B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105348390A (zh) * | 2015-10-26 | 2016-02-24 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
CN105801701A (zh) * | 2016-03-31 | 2016-07-27 | 北京中科励骏生物医学科技有限公司 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
WO2017114230A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
WO2017174017A1 (zh) * | 2016-04-07 | 2017-10-12 | 迈博斯(香港)科技有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
CN107474140A (zh) * | 2016-06-08 | 2017-12-15 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
CN107840892A (zh) * | 2016-09-20 | 2018-03-27 | 上海药明生物技术有限公司 | 新型抗‑pcsk9抗体 |
WO2018054241A1 (en) * | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-pcsk9 antibodies |
WO2020151122A1 (zh) | 2019-01-25 | 2020-07-30 | 浙江蓝盾药业有限公司 | 抗人pcsk9单克隆抗体及其用途 |
CN111620950A (zh) * | 2020-06-16 | 2020-09-04 | 中国药科大学 | 全人源抗pcsk9抗体、其抗原结合片段及其应用 |
CN114438075A (zh) * | 2022-02-25 | 2022-05-06 | 刘博巽 | 一种枯草芽孢杆菌前蛋白酶9靶向结合蛋白的筛选方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476797A (zh) * | 2011-01-28 | 2013-12-25 | 赛诺菲 | 包含针对pcsk9的人抗体的药物组合物 |
WO2015054619A2 (en) * | 2013-10-11 | 2015-04-16 | Sanofi | Use of a pcsk9 inhibitor to treat hyperlipidemia |
-
2015
- 2015-04-27 CN CN201510205553.5A patent/CN104861071B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476797A (zh) * | 2011-01-28 | 2013-12-25 | 赛诺菲 | 包含针对pcsk9的人抗体的药物组合物 |
WO2015054619A2 (en) * | 2013-10-11 | 2015-04-16 | Sanofi | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Non-Patent Citations (2)
Title |
---|
G. TIBOLLA, ET AL.: "Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structureefunction relation to therapeutic inhibition", 《NUTRITION, METABOLISM & CARDIOVASCULAR DISEASES 》 * |
肖文虎等: "PCSK9结构与功能", 《中国生物化学与分子生物学报》 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017071513A1 (zh) * | 2015-10-26 | 2017-05-04 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体及其用途 |
CN105348390A (zh) * | 2015-10-26 | 2016-02-24 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
US10793643B2 (en) | 2015-12-31 | 2020-10-06 | Jiangsu Hengrui Medicine Co., Ltd. | PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof |
WO2017114230A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
CN105801701A (zh) * | 2016-03-31 | 2016-07-27 | 北京中科励骏生物医学科技有限公司 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
CN105801701B (zh) * | 2016-03-31 | 2019-03-29 | 河北仁博科技有限公司 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
WO2017174017A1 (zh) * | 2016-04-07 | 2017-10-12 | 迈博斯(香港)科技有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
CN107266575A (zh) * | 2016-04-07 | 2017-10-20 | 迈博斯(香港)科技有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
US10435477B2 (en) | 2016-04-07 | 2019-10-08 | Mab-Science (Hong Kong) Limited | Proprotein convertase subtilisin kexin type 9 binding proteins and uses thereof |
CN107474140A (zh) * | 2016-06-08 | 2017-12-15 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
CN107474140B (zh) * | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
WO2018054241A1 (en) * | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-pcsk9 antibodies |
US11111313B2 (en) | 2016-09-20 | 2021-09-07 | WuXi Biologics Ireland Limited | Anti-PCSK9 antibodies |
CN107840892A (zh) * | 2016-09-20 | 2018-03-27 | 上海药明生物技术有限公司 | 新型抗‑pcsk9抗体 |
WO2020151122A1 (zh) | 2019-01-25 | 2020-07-30 | 浙江蓝盾药业有限公司 | 抗人pcsk9单克隆抗体及其用途 |
CN111620950A (zh) * | 2020-06-16 | 2020-09-04 | 中国药科大学 | 全人源抗pcsk9抗体、其抗原结合片段及其应用 |
CN114438075A (zh) * | 2022-02-25 | 2022-05-06 | 刘博巽 | 一种枯草芽孢杆菌前蛋白酶9靶向结合蛋白的筛选方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104861071B (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104861071A (zh) | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 | |
JP7293456B2 (ja) | 誘導性結合タンパク質及びその使用方法 | |
Zielonka et al. | Structural insights and biomedical potential of IgNAR scaffolds from sharks | |
TWI582111B (zh) | 一種可屏蔽抗體活性的閉鎖器 | |
Wesolowski et al. | Single domain antibodies: promising experimental and therapeutic tools in infection and immunity | |
US8969082B2 (en) | Expression of surrogate light chains | |
CN108135968A (zh) | 嵌合多肽组装体及其制备和使用方法 | |
KR20210044774A (ko) | Flt3, pd-1 및/또는 pd-l1을 표적으로 하는 면역요법을 위한 조성물 및 방법 | |
UA118028C2 (uk) | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування | |
EA021284B1 (ru) | Антитела и их производные | |
Angelini et al. | Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis | |
US20200223943A1 (en) | Antihuman pcsk9 monoclonal antibody and application thereof | |
CN115996954A (zh) | 治疗感染的方法 | |
EA028178B1 (ru) | Улучшенные связывающие сывороточный альбумин варианты | |
Chan et al. | Naive human antibody libraries for infectious diseases | |
AU2016215087A1 (en) | Tetra-specific, octameric binding agents and antibodies against Clostridium difficile toxin A and toxin B for treatment of C. difficile infection | |
Silva-Pilipich et al. | Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity | |
IL294388A (en) | il2 orthologs and methods of use | |
De Jonge et al. | In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3× anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model | |
Li et al. | A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection | |
Shin et al. | Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy | |
Li et al. | A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells | |
Lin et al. | A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E. coli | |
Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
EP2260863A1 (en) | Prophylactic/therapeutic agent for infectious disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190814 Address after: 210024 No. 122 Ninghai Road, Gulou District, Nanjing City, Jiangsu Province Co-patentee after: ZHEJIANG BLUESHIELD PHARMACY Co.,Ltd. Patentee after: NANJING NORMAL University Address before: Ninghai Gulou District of Nanjing city of Jiangsu Province, No. 122 210097 Patentee before: Nanjing Normal University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190905 Address after: Room 505-506, No. 586 West Ring Road, Keqiao Economic Development Zone, Keqiao District, Shaoxing City, Zhejiang Province Patentee after: ZHEJIANG BLUESHIELD PHARMACY Co.,Ltd. Address before: 210024 No. 122 Ninghai Road, Gulou District, Nanjing City, Jiangsu Province Co-patentee before: ZHEJIANG BLUESHIELD PHARMACY Co.,Ltd. Patentee before: Nanjing Normal University |
|
TR01 | Transfer of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20230207 Granted publication date: 20190412 |
|
PP01 | Preservation of patent right |